New data shared today with Europe’s epilepsy community at the 10th European Congress on Epileptology (ECE) in London, demonstrated the efficacy of Fycompa(R) (perampanel) in reducing partial-onset seizures, the most common form of epilepsy, and its effectiveness and flexibility of use as add-on therapy. 

The successful treatment of partial-onset seizures (the most common form of epilepsy) remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high, despite many existing anti-epileptic drugs (AEDs); between 20 – 40% of patients with epilepsy have remained poorly controlled despite these treatments.[1] The new data supports the use of perampanel as a new therapeutic option for this hard-to-treat patient population.

read more

via Science 2.0 Read More…

Advertisements